NASDAQ: UPCUniverse Pharmaceuticals Inc Stock
$3.77+0.13 (+3.57%)
Updated Jul 10, 2025
UPC Price
$3.77
Fair Value Price
N/A
Market Cap
$2.12M
52 Week Low
$2.51
52 Week High
$2,465.94
P/E
0x
P/B
0.04x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.29M
Earnings
$1.09M
Gross Margin
30.4%
Operating Margin
6.74%
Profit Margin
5.6%
Debt to Equity
0.46
Operating Cash Flow
-$5M
Beta
0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UPC Overview
Universe Pharmaceuticals Incorporated sells traditional Chinese medicines in China. It offers treatments of common chronic health conditions in the elderly and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. Universe Pharmaceuticals was incorporated in 2019 and is based in Ji'An, PRC.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UPC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
UPC
Ranked#34 of 61
Ranked#34 of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $31.14 | A | |
| $3.34 | A | |
| $8.39 | A |
Be the first to know about important UPC news, forecast changes, insider trades & much more!
UPC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UPC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UPC was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UPC is good value based on its earnings relative to its share price (0x), compared to the US market average (30.8x)
P/E vs Market Valuation
UPC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more UPC due diligence checks available for Premium users.
Valuation
UPC fair value
Fair Value of UPC stock based on Discounted Cash Flow (DCF)
Price
$3.77
Fair Value
-$3.53
Undervalued by
206.92%
UPC was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
UPC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-28.49x
Market
30.8x
UPC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
UPC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
UPC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.04x
Industry
2.24x
UPC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UPC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
UPC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
UPC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$80.7M
Liabilities
$25.5M
Debt to equity
0.46
UPC's short-term assets ($65.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UPC's short-term assets ($65.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UPC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
UPC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UPC vs Pharmaceutical Stocks
Universe Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.